Candel Therapeutics Reports Highly Positive Extended Phase 3 Data for Prostate Cancer Drug CAN-2409, Plans Q4 2026 BLA Submission
CADL has more than doubled off its 52-week low of $4.35 on elevated volume (2.0× avg).
Summary
Candel Therapeutics reported compelling extended Phase 3 data for its prostate cancer therapy, CAN-2409, demonstrating significant improvements in disease-free survival and reduced metastasis, with a BLA submission planned for Q4 2026.
Key Events · Product Development and Regulatory · CADL
-
Extended Phase 3 Data Confirms Efficacy
Extended follow-up data from the Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer showed a statistically significant 39% improvement in prostate cancer-specific disease-free survival (HR=0.61; p=0.0031) after a median follow-up of 58 months.
-
Significant Reduction in Metastasis
In the intermediate-risk prostate cancer subgroup (85% of patients), treatment with CAN-2409 resulted in a statistically significant 90% reduction in time to metastasis (HR=0.1; 95% CI 0.01-0.85) and a lower metastasis rate.
-
Favorable Tolerability Profile
CAN-2409 in combination with standard-of-care radiation was generally well tolerated, with most treatment-related adverse events being mild to moderate and no Grade ≥4 events reported.
-
BLA Submission Planned for Q4 2026
The company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CAN-2409 in the fourth quarter of 2026.
Analysis · CADL · Life Sciences
Candel Therapeutics announced highly positive extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer. The data reinforces the drug's efficacy, showing a statistically significant 39% improvement in prostate cancer-specific disease-free survival and a remarkable 90% reduction in time to metastasis in the intermediate-risk subgroup. This strong clinical validation, coupled with a favorable tolerability profile and the company's plan to submit a Biologics License Application (BLA) in Q4 2026, significantly de-risks the drug's path to market and could establish a new standard of care. This news comes as the stock trades near its 52-week high, suggesting strong investor confidence in the drug's potential.
At the time of this filing, CADL was trading at $8.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642.4M. The 52-week trading range was $4.35 to $9.27. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.